Navigation Links
Jennerex and Green Cross Announce Publication of Positive Clinical Data of JX-594 in Combination With Sorafenib in Advanced Liver Cancer
Date:4/20/2011

ial of JX-594 used as a single agent, will evaluate survival in advanced HCC patients who have progressed after treatment with sorafenib," stated David H. Kirn, M.D., president and chief executive officer of Jennerex.

"While the subset of patients in this trial is small, the data are quite compelling.  In prior studies we have demonstrated JX-594's ability to induce necrotic responses as a single agent. This is the first publication showing that JX-594 may sensitize tumors to subsequent treatment with VEGFR inhibitors, such as sorafenib," stated BG Rhee, Ph.D., president, Green Cross Corporation.

The publication also highlighted a case report of a complete and durable response in a patient with metastatic renal cell carcinoma (RCC) who received JX-594 in a Phase 1 intratumoral dose-escalation trial.  The patient, who had a baseline life expectancy of less than six months, had locally bulky and widely metastatic RCC.  The patient received four intratumoral injections of JX-594 and subsequently received standard therapy with sunitinib, an approved drug for RCC of the same class as sorafenib.  CT and PET scanning showed a whole-body complete response, and the patient remains alive and disease-free over four years after treatment initiation.  

About JX-594

JX-594 is a proprietary, engineered oncolytic virus that is designed to selectively target and destroy cancer cells. JX-594 is designed to attack cancer through three diverse mechanisms of action: the lysis of cancer cells through viral replication, the reduction of the blood supply to tumors through vascular targeting and destruction, and the stimulation of the body's immune response against cancer cells, i.e., active immunotherapy. Phase 1 and Phase 2 clinical trials in multiple cancer types to date have shown that JX-594, delivered either directly into tumors or systemically, induces tumor shrinkage and/or necrosis and is well-tolerated by patients. Object
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
2. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
3. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
6. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
7. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
8. Jennerex Announces Presentations at Upcoming Conferences
9. Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
10. Jennerex Appoints Lara Longpre to Chief Operating Officer
11. Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013  Sorrento Therapeutics, Inc. ... Fast-Track Advanced Technology Small Business Technology Transfer Research ... Allergy and Infectious Diseases (NIAID), a division of ... development of novel human antibody therapeutics to combat ... or Staph) infections, including methicillin-resistant S. aureus ...
(Date:5/17/2013)... 17, 2013  Sony Biotechnology Inc. ("Sony") today announced ... (SP6800).  Sony will be exhibiting and taking orders for ... at the San Diego Convention ... from May 20 - 22.  The ... commercial audio-visual technologies into new and novel functionalities for ...
(Date:5/17/2013)... , May 17, 2013 /PRNewswire-iReach/ -- The escalation ... proteins, is placing renewed emphasis on alternate delivery ... as a number of factors are converging to ... makers and their delivery device partners . These ... conditions, the growing trend toward self-administration for chronic ...
Breaking Medicine Technology:Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4Sony Biotechnology Inc.'s New Technology for Science Provides Researchers Results in Color 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3
... 2011 Sanofi (EURONEXT: SAN and NYSE: ... of its dermatology business, Dermik, to Valeant Pharmaceuticals ... cash consideration of US $425 million. Valeant is ... dermatology therapeutic areas, based in Mississauga, Ontario, Canada. ...
... Pa., July 11, 2011 In a study sponsored ... company, scientists from the University of Massachusetts, Amherst presented ... was active against lice eggs from permethrin resistant head ... on Saturday, July 9, 2011 at the 37th ...
Cached Medicine Technology:Sanofi Divests Dermik Dermatology Unit to Valeant Pharmaceuticals International, Inc. 2Sanofi Divests Dermik Dermatology Unit to Valeant Pharmaceuticals International, Inc. 3Sanofi Divests Dermik Dermatology Unit to Valeant Pharmaceuticals International, Inc. 4Topaz Pharmaceuticals' Ivermectin Cream In Vitro Data Demonstrates Activity Against Head Lice Eggs 2
(Date:5/19/2013)... Vegas Hotel Escapes, the premier Las ... launch it's all new vacation packages for the upcoming ... Consumers traveling to Las Vegas will be pleased to ... website. Travelers will be pleased to know that VegasHotelEscapes.com ... Vegas Hotel Escapes specializes in helping consumers Las ...
(Date:5/19/2013)... Beginning Wednesday, May 29 and running through ... will feature “Hot Dog Wednesdays" and Ice Cold Slushies at ... hot dogs and all the fixin's to donors on Wednesdays. ... the summer. “Donors are our lifeline. The summer months are ... blood supply. This is a small way for us ...
(Date:5/19/2013)... FL (PRWEB) May 19, 2013 The ... the website YazSideEffects.com in a concerted effort to connect ... the combination birth control drugs Yaz, Yasmin & Ocella ... a wealth of information on the notorious birth control ... against Bayer Pharmaceuticals. , Yaz, Yasmin & Ocella ...
(Date:5/18/2013)... The American Society for Gastrointestinal Endoscopy (ASGE) will honor ... ninth annual ASGE Crystal Awards on Sunday, May 19, ... year,s event will begin at ... Held in conjunction with Digestive Disease Week (DDW), the ... and scientific pursuit. The event will recognize the 2013 ...
(Date:5/18/2013)... Illuminations is proud to present the Inner ... will take place over the course of four days, on ... Saturday, June 8, 2013. , Inner Child Therapy is concerned ... the attitudes, patterns and coping mechanisms that create the behavior ... to live a more integrated and balanced life style, to ...
Breaking Medicine News(10 mins):Health News:Hot Dog Wednesdays and Ice Cold Slushies Return to Rock River Valley Blood Center for the Summer 2Health News:Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers 2Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 2Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 3Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 4Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 5Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 6Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 7Health News:Illuminations Brings World Renowned Therapist to the Middle East 2
... a significant problem for American children, who miss about 1.6 million ... A new study published in the July issue of the journal ... of children have never seen a dentist and that disparities exist ... the duration between dental care visits. The study, ...
... Stone ... Showing a 9.9 Year Survival Rate. ,Success of Less Invasive Procedures for Knee ... ... 2010 -- Biologic knee repair, rather than bionic (artificial) replacement, may slow the progression ...
... -- Cosmetic contact lenses that give wearers an exaggerated ... among teenagers and young adults," the American Academy of ... "circle" lens extends beyond the iris and, in doing ... the young increased recently after pop star Lady Gaga ...
... ... the quality of family’s lives by providing the healthiest and most practical pool care ... and ultimately “greener” in nature. Pool Joe is determined to offer and encourage their ... , ...
... July 2010: Frontiers in Cardiovascular Biology ( ... organised by the Council on Basic Cardiovascular ... Society of Cardiology (ESC), is being held ... new European platform for the exchange of ...
... , ... Foundation Announced Today Construction of a State-of-the-Art Hospital in Rural Kenya. Founded by ... a Patient. The Foundation,s Investment Management Approach to African Philanthropy is a Departure ... ...
Cached Medicine News:Health News:1 in 4 Californian children have never seen a dentist, study finds 2Health News:Combination of Meniscus Allograft Transplantation and Repair of Articular Cartilage May Slow the Progression of Arthritis in the Knee 2Health News:Lady Gaga-Inspired Lens Fad Draws Warning From Eye Docs 2Health News:Los Angeles Pool Service Company Pool Joe is Going Organic using Eco-Safe Pool Products 2Health News:Frontiers in Cardiovascular Biology: July 16-19, 2010, Berlin, Germany 2Health News:State of the Art Hospital for Rural Kenya Announced by California Foundation 2Health News:State of the Art Hospital for Rural Kenya Announced by California Foundation 3
... Plus IgM Controls identify trends ... your ToRCH IgM immunoassay testing ... results. Liquichek ToRCH Plus IgM ... to Liquichek ToRCH Plus Controls ...
Each Liquichek Seroconversion Panel features a series of serum specimens drawn over time from one individual to show the progression from a negative to a positive disease state....
... are liquid controls designed to ... procedures that detect Chlamydia trachomatis ... are specimen specific, they can ... or endocervical/urethral swabs throughout the ...
Liquichek™ Ethanol/Ammonia Control is a liquid product used to monitor ethanol and ammonia test procedures in the clinical laboratory....
Medicine Products: